Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders

Alan Breier, Emily Liffick, Tom A. Hummer, Jenifer Vohs, Ziyi Yang, Nicole F. Mehdiyoun, Andrew C. Visco, Emmalee Metzler, Ying Zhang, Michael M. Francis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Currently approved medications for schizophrenia are relatively ineffective for negative symptoms and cognitive impairment. N-Acetyl Cysteine (NAC) is a neuroprotective agent that improved general symptoms, cognitive impairment and negative symptoms in some but not all studies, but failed to improve positive symptoms in patients with schizophrenia. Progressive brain mass loss (PBML) has been consistently observed in early phase schizophrenia. NAC mitigates the deleterious effects oxidative stress, inflammation and glutamatergic excitotoxicity and these three pathological processes are hypothesized to contribute to PBML. Methods: In this study, we assessed the effects NAC (3600 mg/day) in a 52-week, double-blind, placebo controlled trial on symptoms, and cognition in early phase schizophrenia spectrum disorders (N = 60). In the context of the clinical trial, we explored the effects of NAC on brain morphology. Results: NAC significantly improved (time × group) PANSS total (F = 14.7, p < 0.001), negative (F = 5.1, p = 0.024) and disorganized thought (F = 13.7, p < 0.001) symptom scores. NAC failed to improve PANSS positive symptoms and BACS cognitive scores. In preliminary analyses, baseline right (r = −0.48, p = 0.041) and left (r = −0.45, p = 0.018) total cortical thickness, and thickness in other cortical regions, were associated with NAC related improvement in PANSS total scores, but NAC, as compared to placebo, did not significantly impact brain morphology over the study treatment period. Conclusions: These results replicate some but not all previous findings of NAC efficacy. Preliminary results suggest that NAC's symptom effects may be related to structural integrity, but NAC failed to demonstrate treatment effects on longitudinal measures of brain morphology. ClinicalTrials.gov Identifier: NCT01339858

Original languageEnglish (US)
JournalSchizophrenia Research
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cognition
Cysteine
Schizophrenia
Brain
Placebos
Neurobehavioral Manifestations
Neuroprotective Agents
Pathologic Processes
Oxidative Stress
Clinical Trials
Inflammation
Therapeutics

Keywords

  • Cognitive impairment
  • Early phase schizophrenia spectrum disorders
  • N-acetyl cysteine
  • Negative symptoms
  • Positive symptoms
  • Progressive brain mass loss

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. / Breier, Alan; Liffick, Emily; Hummer, Tom A.; Vohs, Jenifer; Yang, Ziyi; Mehdiyoun, Nicole F.; Visco, Andrew C.; Metzler, Emmalee; Zhang, Ying; Francis, Michael M.

In: Schizophrenia Research, 01.01.2018.

Research output: Contribution to journalArticle

@article{fa157a7dc53d48bdb27bcb0287c19caa,
title = "Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders",
abstract = "Background: Currently approved medications for schizophrenia are relatively ineffective for negative symptoms and cognitive impairment. N-Acetyl Cysteine (NAC) is a neuroprotective agent that improved general symptoms, cognitive impairment and negative symptoms in some but not all studies, but failed to improve positive symptoms in patients with schizophrenia. Progressive brain mass loss (PBML) has been consistently observed in early phase schizophrenia. NAC mitigates the deleterious effects oxidative stress, inflammation and glutamatergic excitotoxicity and these three pathological processes are hypothesized to contribute to PBML. Methods: In this study, we assessed the effects NAC (3600 mg/day) in a 52-week, double-blind, placebo controlled trial on symptoms, and cognition in early phase schizophrenia spectrum disorders (N = 60). In the context of the clinical trial, we explored the effects of NAC on brain morphology. Results: NAC significantly improved (time × group) PANSS total (F = 14.7, p < 0.001), negative (F = 5.1, p = 0.024) and disorganized thought (F = 13.7, p < 0.001) symptom scores. NAC failed to improve PANSS positive symptoms and BACS cognitive scores. In preliminary analyses, baseline right (r = −0.48, p = 0.041) and left (r = −0.45, p = 0.018) total cortical thickness, and thickness in other cortical regions, were associated with NAC related improvement in PANSS total scores, but NAC, as compared to placebo, did not significantly impact brain morphology over the study treatment period. Conclusions: These results replicate some but not all previous findings of NAC efficacy. Preliminary results suggest that NAC's symptom effects may be related to structural integrity, but NAC failed to demonstrate treatment effects on longitudinal measures of brain morphology. ClinicalTrials.gov Identifier: NCT01339858",
keywords = "Cognitive impairment, Early phase schizophrenia spectrum disorders, N-acetyl cysteine, Negative symptoms, Positive symptoms, Progressive brain mass loss",
author = "Alan Breier and Emily Liffick and Hummer, {Tom A.} and Jenifer Vohs and Ziyi Yang and Mehdiyoun, {Nicole F.} and Visco, {Andrew C.} and Emmalee Metzler and Ying Zhang and Francis, {Michael M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.schres.2018.03.012",
language = "English (US)",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders

AU - Breier, Alan

AU - Liffick, Emily

AU - Hummer, Tom A.

AU - Vohs, Jenifer

AU - Yang, Ziyi

AU - Mehdiyoun, Nicole F.

AU - Visco, Andrew C.

AU - Metzler, Emmalee

AU - Zhang, Ying

AU - Francis, Michael M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Currently approved medications for schizophrenia are relatively ineffective for negative symptoms and cognitive impairment. N-Acetyl Cysteine (NAC) is a neuroprotective agent that improved general symptoms, cognitive impairment and negative symptoms in some but not all studies, but failed to improve positive symptoms in patients with schizophrenia. Progressive brain mass loss (PBML) has been consistently observed in early phase schizophrenia. NAC mitigates the deleterious effects oxidative stress, inflammation and glutamatergic excitotoxicity and these three pathological processes are hypothesized to contribute to PBML. Methods: In this study, we assessed the effects NAC (3600 mg/day) in a 52-week, double-blind, placebo controlled trial on symptoms, and cognition in early phase schizophrenia spectrum disorders (N = 60). In the context of the clinical trial, we explored the effects of NAC on brain morphology. Results: NAC significantly improved (time × group) PANSS total (F = 14.7, p < 0.001), negative (F = 5.1, p = 0.024) and disorganized thought (F = 13.7, p < 0.001) symptom scores. NAC failed to improve PANSS positive symptoms and BACS cognitive scores. In preliminary analyses, baseline right (r = −0.48, p = 0.041) and left (r = −0.45, p = 0.018) total cortical thickness, and thickness in other cortical regions, were associated with NAC related improvement in PANSS total scores, but NAC, as compared to placebo, did not significantly impact brain morphology over the study treatment period. Conclusions: These results replicate some but not all previous findings of NAC efficacy. Preliminary results suggest that NAC's symptom effects may be related to structural integrity, but NAC failed to demonstrate treatment effects on longitudinal measures of brain morphology. ClinicalTrials.gov Identifier: NCT01339858

AB - Background: Currently approved medications for schizophrenia are relatively ineffective for negative symptoms and cognitive impairment. N-Acetyl Cysteine (NAC) is a neuroprotective agent that improved general symptoms, cognitive impairment and negative symptoms in some but not all studies, but failed to improve positive symptoms in patients with schizophrenia. Progressive brain mass loss (PBML) has been consistently observed in early phase schizophrenia. NAC mitigates the deleterious effects oxidative stress, inflammation and glutamatergic excitotoxicity and these three pathological processes are hypothesized to contribute to PBML. Methods: In this study, we assessed the effects NAC (3600 mg/day) in a 52-week, double-blind, placebo controlled trial on symptoms, and cognition in early phase schizophrenia spectrum disorders (N = 60). In the context of the clinical trial, we explored the effects of NAC on brain morphology. Results: NAC significantly improved (time × group) PANSS total (F = 14.7, p < 0.001), negative (F = 5.1, p = 0.024) and disorganized thought (F = 13.7, p < 0.001) symptom scores. NAC failed to improve PANSS positive symptoms and BACS cognitive scores. In preliminary analyses, baseline right (r = −0.48, p = 0.041) and left (r = −0.45, p = 0.018) total cortical thickness, and thickness in other cortical regions, were associated with NAC related improvement in PANSS total scores, but NAC, as compared to placebo, did not significantly impact brain morphology over the study treatment period. Conclusions: These results replicate some but not all previous findings of NAC efficacy. Preliminary results suggest that NAC's symptom effects may be related to structural integrity, but NAC failed to demonstrate treatment effects on longitudinal measures of brain morphology. ClinicalTrials.gov Identifier: NCT01339858

KW - Cognitive impairment

KW - Early phase schizophrenia spectrum disorders

KW - N-acetyl cysteine

KW - Negative symptoms

KW - Positive symptoms

KW - Progressive brain mass loss

UR - http://www.scopus.com/inward/record.url?scp=85044281930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044281930&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2018.03.012

DO - 10.1016/j.schres.2018.03.012

M3 - Article

C2 - 29588126

AN - SCOPUS:85044281930

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -